\uff5e RedHill\u793e\u304cVeeva Vault CDMS\u3068Bioforum\u793e\u3092\u9078\u629e\u3057\u3066\u3001<\/p>\n
\u91cd\u75c7\u306e\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u60a3\u8005\u306b\u5bfe\u3059\u308b\u30aa\u30d1\u30ac\u30cb\u30d6\u306e\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b<\/p>\n
\u56fd\u969b\u5171\u540c\u7b2c2\u76f8\uff0f\u7b2c3\u76f8\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u30af\u30ea\u30cb\u30ab\u30eb\u30c7\u30fc\u30bf\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u3092\u6700\u9069\u5316 \uff5e<\/p>\n
<\/p>\n
2020\u5e7411\u670817\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b Veeva) \u3068Bioforum\u793e<\/a><\/strong>\u306f\u3001\u88dc\u52a9\u9178\u7d20\u51e6\u7f6e\u306b\u3088\u308b\u6cbb\u7642\u3092\u5fc5\u8981\u3068\u3059\u308b\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\uff08COVID-19\uff09\u306b\u3088\u308b\u91cd\u75c7\u306e\u80ba\u708e\u5165\u9662\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3057\u305f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306e\u30b9\u30d5\u30a3\u30f3\u30b4\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc2\uff08SK2\uff09\u9078\u629e\u7684\u963b\u5bb3\u5264\u3067\u3042\u308b\u30aa\u30d1\u30ac\u30cb\u30d6<\/a><\/strong>\uff08Yeliva\u00ae\u3001ABC294640\uff09[1]<\/sup><\/a><\/strong>\u306e\u7d4c\u53e3\u6295\u4e0e\u306b\u3088\u308b\u6709\u52b9\u6027\u3092\u8a55\u4fa1\u3059\u308b\u56fd\u969b\u5171\u540c\u7b2c2\u76f8\uff0f\u7b2c3\u76f8\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001RedHill Biopharma\u793e<\/a><\/strong>\u3010Nasdaq: RDHL\u3011\uff08\u4ee5\u4e0b\u3001RedHill\u793e\uff09\u306b\u5354\u529b\u3059\u308b\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002(\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n \u539f\u6587\uff1a https:\/\/www.veeva.com\/resources\/veeva-and-bioforum-partner-with-redhill-biopharma-to-maximize-value-of-opaganib-phase-2-3-covid-19-clinical-data\/<\/p>\n <\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\u306e\u7b2c2\u76f8\uff0f\u7b2c3\u76f8\u8a66\u9a13\u306f\u3001\u5e83\u7bc4\u304b\u3064\u53b3\u5bc6\u306a\u30c7\u30fc\u30bf\u3092\u77ed\u671f\u9593\u3067\u53ce\u96c6\u3059\u308b\u305f\u3081\u306b\u3001\u4e16\u754c\u5404\u5730\u306e\u6700\u592740\u306e\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3067\u6700\u5927270\u4eba\u306e\u88ab\u9a13\u8005\u3092\u767b\u9332\u3059\u308b\u3053\u3068\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8a66\u9a13\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u3001RedHill\u793e\u306fVeeva Vault CDMS<\/a><\/strong>\u3092\u63a1\u7528\u3057\u307e\u3057\u305f\u3002Vault CDMS\u306f\u3001\u96fb\u5b50\u30c7\u30fc\u30bf\u53ce\u96c6\uff08EDC\uff09\u3001\u30b3\u30fc\u30c7\u30a3\u30f3\u30b0\u3001\u30c7\u30fc\u30bf\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3001\u30ec\u30dd\u30fc\u30c8\u4f5c\u6210\u306e\u305f\u3081\u306e\u6700\u65b0\u30af\u30e9\u30a6\u30c9\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u69cb\u7bc9\u304a\u3088\u3073\u5c55\u958b\u30d7\u30ed\u30bb\u30b9\u3092\u30b9\u30ea\u30e0\u5316\u3057\u3066\u52b9\u7387\u5316\u3059\u308b\u3001\u67d4\u8edf\u306aEDC\u3092RedHill\u793e\u306b\u63d0\u4f9b\u3057\u307e\u3059\u3002\u30c7\u30fc\u30bf\u306b\u30d5\u30a9\u30fc\u30ab\u30b9\u3057\u305f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u533b\u85ac\u54c1\u958b\u767a\u696d\u52d9\u53d7\u8a17\u6a5f\u95a2\uff08CRO\uff09\u3067\u3042\u308a\u3001Veeva\u306e\u8a8d\u5b9a\u30d1\u30fc\u30c8\u30ca\u30fc\u3067\u3042\u308bBioforum\u793e\u306f\u3001\u9577\u5e74\u306e\u30af\u30e9\u30a4\u30a2\u30f3\u30c8\u4f01\u696d\u3067\u3042\u308bRedHill\u793e\u306b\u3088\u308a\u3001\u4eca\u56de\u306eCOVID-19\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3051\u308bVault CDMS\u306e\u5b9f\u88c5\u304a\u3088\u3073\u8a2d\u5b9a\u62c5\u5f53\u3068\u3057\u3066\u9078\u3070\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n RedHill\u793e\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30a2\u30d5\u30a7\u30a2\u30fc\u30ba\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bAida Bibliowicz\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u72ec\u81ea\u306e\u6297\u708e\u75c7\u6a5f\u5e8f\u3068\u6297\u30a6\u30a4\u30eb\u30b9\u6a5f\u5e8f\u3092\u517c\u306d\u5099\u3048\u305f\u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u3001\u75be\u60a3\u306e\u4e3b\u8981\u5897\u60aa\u56e0\u5b50\u3092\u963b\u5bb3\u3057\u3001\u91cd\u75c7\u306eCOVID-19\u60a3\u8005\u306b\u5bfe\u3059\u308b\u5b89\u5168\u3067\u6709\u52b9\u306a\u6551\u547d\u6cbb\u7642\u3068\u3044\u3046\u3001\u672a\u89e3\u6c7a\u306e\u6df1\u523b\u306a\u533b\u7642\u30cb\u30fc\u30ba\u306b\u5fdc\u3048\u308b\u3053\u3068\u304c\u671f\u5f85\u3067\u304d\u307e\u3059\u3002\u5f53\u9762\u306e\u76ee\u6a19\u306f\u3001\u30aa\u30d1\u30ac\u30cb\u30d6\u306e\u7dca\u6025\u4f7f\u7528\u306e\u305f\u3081\u306e\u627f\u8a8d\u7533\u8acb\u306e\u53ef\u80fd\u6027\u3092\u5f8c\u62bc\u3057\u3059\u308b\u305f\u3081\u3001\u65e9\u3051\u308c\u30702020\u5e74\u7b2c4\u56db\u534a\u671f\u4e2d\u306b\u3082\u30af\u30ea\u30cb\u30ab\u30eb\u30c7\u30fc\u30bf\u3092\u53ce\u96c6\u3059\u308b\u3053\u3068\u3067\u3059\u3002\u3057\u305f\u304c\u3063\u3066\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u52b9\u7387\u5316\u3068\u8a66\u9a13\u30c7\u30fc\u30bf\u306e\u54c1\u8cea\u3068\u5b8c\u5168\u6027\u304c\u6975\u3081\u3066\u91cd\u8981\u3067\u3042\u308a\u3001\u305d\u306e\u78ba\u4fdd\u306e\u305f\u3081\u306bBioforum\u793e\u3068Veeva\u306e\u5354\u529b\u304c\u5f97\u3089\u308c\u308b\u3053\u3068\u3092\u3046\u308c\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u300d<\/p>\n Vault CDMS\u306f\u3001\u6cbb\u9a13\u4f9d\u983c\u8005\u3068CRO\u30d1\u30fc\u30c8\u30ca\u30fc\u304c\u81e8\u5e8a\u8a66\u9a13\u306e\u69cb\u7bc9\u304b\u3089\u5b9f\u65bd\u307e\u3067\u3092\u5354\u529b\u3057\u3066\u7ba1\u7406\u3067\u304d\u308b\u3088\u3046\u306b\u3057\u307e\u3059\u3002Vault CDMS\u306e\u4e00\u90e8\u3067\u3042\u308bVeeva Vault EDC<\/a><\/strong>\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u30c7\u30fc\u30bf\u53ce\u96c6\u306e\u305f\u3081\u306e\u76f4\u611f\u7684\u306a\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30fc\u30b9\u3092\u5099\u3048\u3001\u67d4\u8edf\u6027\u3092\u91cd\u8996\u3057\u3066\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u305d\u306e\u305f\u3081\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u4f53\u5236\u3092\u8fc5\u901f\u306b\u69cb\u7bc9\u3057\u3001\u8a66\u9a13\u671f\u9593\u4e2d\u3082\u30c0\u30a6\u30f3\u30bf\u30a4\u30e0\u304c\u767a\u751f\u3059\u308b\u3053\u3068\u306a\u304f\u8a66\u9a13\u30c7\u30b6\u30a4\u30f3\u3092\u5909\u66f4\u3067\u304d\u307e\u3059\u3002<\/p>\n Veeva\u306eVault CDMS\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u304a\u3088\u3073\u60a3\u8005\u5411\u3051\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u62c5\u5f53\u306e\u30bc\u30cd\u30e9\u30eb\u30de\u30cd\u30fc\u30b8\u30e3\u30fc\u3067\u3042\u308bHenry Levy\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300cRedHill\u793e\u306e\u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u3001\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u3092\u514b\u670d\u3059\u308b\u305f\u3081\u306b\u5fc5\u8981\u306a\u533b\u85ac\u54c1\u5019\u88dc\u3068\u3057\u3066\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u5f53\u793e\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3068Bioforum\u793e\u3068\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u304c\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u63a8\u9032\u306e\u304a\u5f79\u306b\u7acb\u3066\u308b\u3053\u3068\u3092\u3046\u308c\u3057\u304f\u601d\u3044\u307e\u3059\u3002RedHill\u793e\u3068\u5171\u306b\u3001COVID-19\u60a3\u8005\u306e\u547d\u3092\u6551\u3044\u3001\u75c7\u72b6\u3092\u6539\u5584\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u3053\u306e\u91cd\u8981\u306a\u6cbb\u7642\u6cd5\u3092\u524d\u9032\u3055\u305b\u308b\u3053\u3068\u3092\u697d\u3057\u307f\u306b\u3057\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n Bioforum\u793e\u306e\u5171\u540c\u5275\u696d\u8005\u517c\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bAmir Malka\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u3053\u306e\u91cd\u8981\u306aCOVID-19\u81e8\u5e8a\u8a66\u9a13\u306b\u8ca2\u732e\u3067\u304d\u308b\u3053\u3068\u3092\u8a87\u308a\u306b\u601d\u3044\u307e\u3059\u3002RedHill\u793e\u3068\u306e\u9577\u5e74\u306b\u308f\u305f\u308b\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u7d99\u7d9a\u3057\u3001\u4eca\u56de\u3082\u30b0\u30ed\u30fc\u30d0\u30eb\u81e8\u5e8a\u958b\u767a\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u8fc5\u901f\u306b\u524d\u9032\u3055\u305b\u3001\u60a3\u8005\u306e\u751f\u6d3b\u306b\u610f\u5473\u306e\u3042\u308b\u6539\u5584\u3092\u3082\u305f\u3089\u3059\u6cbb\u7642\u6cd5\u3092\u63d0\u4f9b\u3059\u308b\u53d6\u308a\u7d44\u307f\u3092\u652f\u63f4\u3057\u307e\u3059\u3002Veeva\u3068\u5354\u529b\u3059\u308b\u3053\u3068\u3067\u3001RedHill\u793e\u306e\u3088\u3046\u306a\u30af\u30e9\u30a4\u30a2\u30f3\u30c8\u4f01\u696d\u304c\u8a66\u9a13\u30c7\u30b6\u30a4\u30f3\u304b\u3089\u7acb\u3061\u4e0a\u3052\u3001\u5b9f\u65bd\u3001\u7533\u8acb\u306b\u81f3\u308b\u307e\u3067\u306e\u81e8\u5e8a\u958b\u767a\u306e\u3042\u3089\u3086\u308b\u6bb5\u968e\u3092\u52b9\u7387\u5316\u3059\u308b\u304a\u624b\u4f1d\u3044\u3092\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3082\u306e\u3068\u78ba\u4fe1\u3057\u3066\u3044\u307e\u3059\u3002\u300d<\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\uff08Yeliva\u00ae\u3001ABC294640\uff09\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u8a73\u7d30\u306f\u3001www.redhillbio.com<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n <\/p>\n \u3010<\/strong>\u30aa\u30d1\u30ac\u30cb\u30d6\uff08<\/strong>ABC294640<\/strong>\u3001<\/strong>Yeliva\u00ae<\/strong>\uff09<\/strong>\u306b\u3064\u3044\u3066\u3011<\/strong> \u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u3001\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u304b\u3089\u80c6\u7ba1\u304c\u3093\u6cbb\u7642\u7528\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u9032\u884c\u6027\u80c6\u7ba1\u304c\u3093\u306b\u5bfe\u3059\u308b\u524d\u671f\u7b2c2\u76f8\u8a66\u9a13\u304a\u3088\u3073\u524d\u7acb\u817a\u304c\u3093\u306b\u5bfe\u3059\u308b\u7b2c2\u76f8\u8a66\u9a13\u3067\u8a55\u4fa1\u304c\u884c\u308f\u308c\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\uff08COVID-19\uff09\u306b\u5bfe\u3059\u308b\u56fd\u969b\u5171\u540c\u7b2c2\u76f8\uff0f\u7b2c3\u76f8\u8a66\u9a13\u304a\u3088\u3073\u7c73\u56fd\u306b\u304a\u3051\u308b\u7b2c2\u76f8\u8a66\u9a13\u3067\u3082\u8a55\u4fa1\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u524d\u81e8\u5e8a\u30c7\u30fc\u30bf\u306b\u3066\u6297\u708e\u75c7\u6d3b\u6027\u3068\u6297\u30a6\u30a4\u30eb\u30b9\u6d3b\u6027\u3092\u793a\u3057\u3066\u304a\u308a\u3001\u80ba\u708e\u306a\u3069\u306e\u80ba\u708e\u75c7\u6027\u75be\u60a3\u3084\u80ba\u7dda\u7dad\u75c7\u3092\u8efd\u6e1b\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u3001COVID-19\u306e\u539f\u56e0\u30a6\u30a4\u30eb\u30b9\u3067\u3042\u308bSARS-CoV-2\u306b\u5bfe\u3057\u3066\u5f37\u529b\u306a\u6297\u30a6\u30a4\u30eb\u30b9\u6d3b\u6027\u3092\u793a\u3057\u3001\u30d2\u30c8\u80ba\u6c17\u7ba1\u652f\u7d44\u7e54\u306ein vitro<\/em>\u30e2\u30c7\u30eb\u3067\u306f\u30a6\u30a4\u30eb\u30b9\u306e\u8907\u88fd\u3092\u5b8c\u5168\u306b\u963b\u5bb3\u3057\u307e\u3057\u305f\u3002\u3055\u3089\u306b\u3001\u6c17\u7ba1\u652f\u80ba\u80de\u6d17\u6d44\u6db2\u4e2d\u306eIL-6\u304a\u3088\u3073TNF-alpha\u30ec\u30d9\u30eb\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u306b\u3088\u308b\u81f4\u6b7b\u7387\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u307b\u304b\u3001\u7dd1\u81bf\u83cc\u8a98\u767a\u80ba\u969c\u5bb3\u3092\u6539\u5584\u3059\u308b\u3053\u3068\u304c\u524d\u81e8\u5e8a\u306ein vivo<\/em>\u8a66\u9a13[1]<\/sup><\/a>\u3067\u660e\u3089\u304b\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u3001\u3082\u3068\u306f\u7c73\u56fd\u306b\u672c\u793e\u3092\u7f6e\u304fApogee Biotechnology\u793e\u306b\u3088\u3063\u3066\u958b\u767a\u3055\u308c\u305f\u3082\u306e\u3067\u3001\u304c\u3093\u5897\u6b96\u3001\u708e\u75c7\u7cfb\u3001\u6d88\u5316\u5668\u7cfb\u3001\u304a\u3088\u3073\u653e\u5c04\u7dda\u9632\u8b77\u306e\u5404\u7a2e\u30e2\u30c7\u30eb\u306b\u5bfe\u3059\u308b\u524d\u81e8\u5e8a\u8a66\u9a13\u306b\u52a0\u3048\u3001\u9032\u884c\u6027\u306e\u56fa\u5f62\u304c\u3093\u3092\u6709\u3059\u308b\u304c\u3093\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3059\u308b\u7b2c1\u76f8\u8a66\u9a13\u306b\u3082\u6210\u529f\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n \u30b3\u30f3\u30d1\u30c3\u30b7\u30e7\u30cd\u30fc\u30c8\u30fb\u30e6\u30fc\u30b9\u5236\u5ea6\u306e\u4e0b\u3001\u30a4\u30b9\u30e9\u30a8\u30eb\u306e\u5148\u9032\u75c5\u9662\u306b\u304a\u3044\u3066\u30aa\u30d1\u30ac\u30cb\u30d6\u306b\u3088\u308bCOVID-19\u60a3\u8005\uff08WHO\u306e\u9806\u5e8f\u5c3a\u5ea6\u306b\u57fa\u3065\u304f\uff09\u306e\u6cbb\u7642\u304c\u884c\u308f\u308c\u307e\u3057\u305f\u3002\u5148\u9803\u3001\u30aa\u30d1\u30ac\u30cb\u30d6\u306b\u3088\u308b\u3053\u308c\u3089\u306eCOVID-19\u91cd\u75c7\u60a3\u8005\u306e\u521d\u3081\u3066\u306e\u6cbb\u7642\u30c7\u30fc\u30bf\u304c\u516c\u958b\u3055\u308c\u307e\u3057\u305f\u3002[2]<\/sup><\/a> \u6cbb\u7642\u6210\u679c\u3092\u5206\u6790\u3057\u305f\u7d50\u679c\u3001\u540c\u75c5\u9662\u3067\u9061\u53ca\u7684\u306b\u8abf\u3079\u305f\u75c7\u4f8b\u5bfe\u7167\u7fa4\u3068\u306e\u6bd4\u8f03\u306b\u304a\u3044\u3066\u3001\u30b3\u30f3\u30d1\u30c3\u30b7\u30e7\u30cd\u30fc\u30c8\u30fb\u30e6\u30fc\u30b9\u5236\u5ea6\u306e\u4e0b\u3067\u30aa\u30d1\u30ac\u30cb\u30d6\u306b\u3088\u3063\u3066\u6cbb\u7642\u3057\u305f\u60a3\u8005\u3067\u306f\u3001\u81e8\u5e8a\u8ee2\u5e30\u3068\u708e\u75c7\u30de\u30fc\u30ab\u30fc\u306e\u4e21\u9762\u3067\u975e\u5e38\u306b\u6709\u52b9\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u307e\u3057\u305f\u3002\u30aa\u30d1\u30ac\u30cb\u30d6\u6295\u4e0e\u7fa4\u306e\u60a3\u8005\u306f\u5168\u54e1\u304c\u4eba\u5de5\u547c\u5438\u5668\u306e\u5fc5\u8981\u306a\u304f\u9000\u9662\u3057\u305f\u306e\u306b\u5bfe\u3057\u3001\u75c7\u4f8b\u5bfe\u7167\u7fa4\u306f33%\u306e\u60a3\u8005\u306b\u4eba\u5de5\u547c\u5438\u5668\u304c\u5fc5\u8981\u3067\u3057\u305f\u3002\u307e\u305f\u3001\u9ad8\u6d41\u91cf\u5f0f\u9f3b\u30ab\u30cb\u30e5\u30fc\u30ec\u96e2\u8131\u307e\u3067\u306e\u4e2d\u592e\u5024\u306f\u3001\u5bfe\u7167\u7fa4\u306e15\u65e5\u306b\u5bfe\u3057\u3001\u30aa\u30d1\u30ac\u30cb\u30d6\u6295\u4e0e\u7fa4\u3067\u306f10\u65e5\u306b\u77ed\u7e2e\u3055\u308c\u307e\u3057\u305f\u3002<\/a><\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\u306e\u958b\u767a\u306f\u3001\u56fd\u7acb\u304c\u3093\u7814\u7a76\u6240\uff08NCI\uff09\u3001\u751f\u7269\u533b\u5b66\u5148\u7aef\u7814\u7a76\u958b\u767a\u5c40\uff08BARDA\uff09\u3001\u56fd\u9632\u7dcf\u7701\u3001FDA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u958b\u767a\u5ba4\uff08OOPD\uff09\u306a\u3069\u306e\u7c73\u56fd\u9023\u90a6\u653f\u5e9c\u304a\u3088\u3073\u5dde\u653f\u5e9c\u6a5f\u95a2\u304b\u3089Apogee Biotechnology Corp\u793e\u306b\u6388\u4e0e\u3055\u308c\u305f\u88dc\u52a9\u91d1\u3084\u5951\u7d04\u306b\u3088\u3063\u3066\u652f\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n \u30aa\u30d1\u30ac\u30cb\u30d6\u306b\u95a2\u3059\u308b\u9032\u884c\u4e2d\u306e\u8a66\u9a13\u306f\u3001\u516c\u7684\u304a\u3088\u3073\u6c11\u9593\u306b\u3088\u3063\u3066\u652f\u63f4\u3055\u308c\u3066\u3044\u308b\u81e8\u5e8a\u8a66\u9a13\u306b\u95a2\u3059\u308b\u60c5\u5831\u3092\u516c\u958b\u3057\u3066\u3044\u308b\u3001\u7c73\u56fd\u56fd\u7acb\u885b\u751f\u7814\u7a76\u6240\uff08NIH\uff09\u306eWeb\u30d9\u30fc\u30b9\u306e\u30b5\u30fc\u30d3\u30b9\uff08www.clinicaltrials.gov<\/a>\uff09\u306b\u767b\u9332\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n \u00a0<\/strong><\/p>\n \u3010<\/strong>RedHill Biopharma<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u4e3b\u306b\u6d88\u5316\u5668\u75be\u60a3\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u305f\u30b9\u30da\u30b7\u30e3\u30eb\u30c6\u30a3\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u3067\u3059\u3002RedHill\u793e\u306f\u3001\u6210\u4eba\u5411\u3051\u30aa\u30d4\u30aa\u30a4\u30c9\u8a98\u767a\u6027\u4fbf\u79d8\u6cbb\u7642\u85ac\u300cMovantik\u00ae<\/sup>\u300d[i]<\/sup><\/a>\u3001\u6210\u4eba\u5411\u3051\u30d8\u30ea\u30b3\u30d0\u30af\u30bf\u30fc\u30d4\u30ed\u30ea<\/em>\u611f\u67d3\u75c7\u6cbb\u7642\u85ac\u300cTalicia\u00ae<\/sup>\u300d[ii]<\/sup><\/a>\u3001\u304a\u3088\u3073\u6210\u4eba\u5411\u3051\u65c5\u884c\u8005\u4e0b\u75e2\u75c7\u6cbb\u7642\u85ac\u300cAemcolo\u00ae<\/sup>\u300d[iii]<\/sup><\/a>\u306e\u8ca9\u58f2\u3092\u884c\u3063\u3066\u3044\u307e\u3059\u3002RedHill\u793e\u306e\u4e3b\u306a\u5f8c\u671f\u81e8\u5e8a\u958b\u767a\u30d7\u30ed\u30b0\u30e9\u30e0\u3068\u3057\u3066\u306f\u3001(i) \u80ba\u975e\u7d50\u6838\u6027\u30de\u30a4\u30b3\u30d0\u30af\u30c6\u30ea\u30a2\u611f\u67d3\u75c7\uff08NTM\uff09\u306b\u5bfe\u3059\u308b\u30d4\u30dc\u30bf\u30eb\u7b2c3\u76f8\u8a66\u9a13\u304c\u8a08\u753b\u3055\u308c\u3066\u3044\u308bRHB-204\u3001(ii) \u3055\u307e\u3056\u307e\u306a\u9069\u5fdc\u75c7\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u306b\u3057\u305f\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306eSK2\u9078\u629e\u7684\u963b\u5bb3\u5264\u3067\u3001COVID-19\u306b\u5bfe\u3059\u308b\u7b2c2\u76f8\uff0f\u7b2c3\u76f8\u8a66\u9a13\u306a\u3089\u3073\u306b\u524d\u7acb\u817a\u304c\u3093\u304a\u3088\u3073\u80c6\u7ba1\u304c\u3093\u306b\u5bfe\u3059\u308b\u7b2c2\u76f8\u8a66\u9a13\u304c\u9032\u884c\u4e2d\u306e\u30aa\u30d1\u30ac\u30cb\u30d6\uff08Yeliva\u00ae<\/sup>\uff09\u3001(iii) \u30af\u30ed\u30fc\u30f3\u75c5\u306b\u5bfe\u3059\u308b\u6700\u521d\u306e\u7b2c3\u76f8\u8a66\u9a13\u304b\u3089\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u3066\u3044\u308bRHB-104\u3001(iv) \u6025\u6027\u80c3\u8178\u708e\u304a\u3088\u3073\u80c3\u708e\u306b\u5bfe\u3059\u308b\u7b2c3\u76f8\u8a66\u9a13\u306a\u3089\u3073\u306b\u6162\u6027\u4e0b\u75e2\u578b\u904e\u654f\u6027\u8178\u75c7\u5019\u7fa4\uff08IBS-D\uff09\u306b\u5bfe\u3059\u308b\u7b2c2\u76f8\u8a66\u9a13\u304b\u3089\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u3066\u3044\u308bRHB-102\uff08Bekinda\u00ae<\/sup>\uff09\u3001(v) \u304c\u3093\u304a\u3088\u3073\u708e\u75c7\u6027\u6d88\u5316\u5668\u75be\u60a3\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u306b\u3057\u305f\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306e\u30bb\u30ea\u30f3\u30d7\u30ed\u30c6\u30a2\u30fc\u30bc\u963b\u5bb3\u5264\u3067\u3001\u7b2c2\u76f8\u8a66\u9a13\u6bb5\u968e\u306b\u3042\u308a\u3001COVID-19\u306b\u5bfe\u3057\u3066\u3082\u8a55\u4fa1\u304c\u884c\u308f\u308c\u3066\u3044\u308bRHB-107\u3001(vi) \u30ab\u30d7\u30bb\u30eb\u5316\u8178\u6eb6\u88fd\u5264\u3067\u3042\u308bRHB-106\u306a\u3069\u304c\u3042\u308a\u307e\u3059\u3002RedHill\u793e\u306e\u8a73\u7d30\u306fwww.redhillbio.com<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/a><\/p>\n \u00a0<\/strong><\/p>\n \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> <\/p>\n \u3010Forward-looking Statements Regarding Veeva and its Products\u3011 <\/p>\n \u3010Forward-looking Statements Regarding RedHill and Opaganib\u3011 <\/p>\n <\/p>\n [1]<\/sup><\/a> \u30aa\u30d1\u30ac\u30cb\u30d6\u306f\u6cbb\u9a13\u85ac\u3067\u3042\u308a\u3001\u5e02\u8ca9\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002 \u91cd\u75c7\u306eCOVID-19\u60a3\u8005\u5411\u3051\u6cbb\u7642\u85ac\u306e\u7dca\u6025\u4f7f\u7528\u306e\u305f\u3081\u306e\u627f\u8a8d\u7533\u8acb\u306b\u5411\u3051\u3066\u3001\u81e8\u5e8a\u8a66\u9a13\u3092\u8fc5\u901f\u5316\u3059\u308b\u305f\u3081\u306bRedHill\u793e\u306fVeeva Vault CDMS\u3092\u63a1\u7528\u3002<\/p>\n","protected":false},"author":131,"featured_media":44108,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-44241","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44241"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=44241"}],"version-history":[{"count":8,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44241\/revisions"}],"predecessor-version":[{"id":44252,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/44241\/revisions\/44252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media\/44108"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=44241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=44241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=44241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\u65b0\u898f\u5316\u5b66\u7269\u8cea\u300c\u30aa\u30d1\u30ac\u30cb\u30d6\u300d\u306f\u3001\u6297\u304c\u3093\u3001\u6297\u708e\u75c7\u3001\u304a\u3088\u3073\u6297\u30a6\u30a4\u30eb\u30b9\u6d3b\u6027\u3092\u793a\u3059\u72ec\u81ea\u958b\u767a\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30a4\u30f3\u30af\u30e9\u30b9\u306e\u7d4c\u53e3\u6295\u4e0e\u30b9\u30d5\u30a3\u30f3\u30b4\u30b7\u30f3\u30ad\u30ca\u30fc\u30bc2\uff08SK2\uff09\u9078\u629e\u7684\u963b\u5bb3\u5264\u3067\u3042\u308a\u3001\u3055\u307e\u3056\u307e\u306a\u304c\u3093\u816b\u3001\u30a6\u30a4\u30eb\u30b9\u6027\u75be\u60a3\u3001\u708e\u75c7\u6027\u75be\u60a3\u3001\u304a\u3088\u3073\u6d88\u5316\u5668\u75be\u60a3\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u306b\u3057\u3066\u3044\u307e\u3059\u3002SK2\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u304c\u3093\u5897\u6b96\u3001\u30a6\u30a4\u30eb\u30b9\u8907\u88fd\u3001\u304a\u3088\u3073\u75c5\u7684\u708e\u75c7\u306b\u95a2\u9023\u3059\u308b\u8907\u6570\u306e\u7d30\u80de\u6027\u306e\u7d4c\u8def\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u307e\u3059\u3002<\/p>\n
\nRedHill Biopharma\u793e\u3010Nasdaq:RDHL<\/a>\u3011\u306f\u3001<\/p>\n
\nVeeva Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u3001900\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002Veeva\u306f\u3001\u30b5\u30f3\u30d5\u30e9\u30f3\u30b7\u30b9\u30b3\u306e\u30d9\u30a4\u30a8\u30ea\u30a2\u306b\u672c\u793e\u3092\u7f6e\u304d\u3001\u30e8\u30fc\u30ed\u30c3\u30d1\u3001\u30a2\u30b8\u30a2\u3001\u30e9\u30c6\u30f3\u30a2\u30e1\u30ea\u30ab\u306b\u62e0\u70b9\u3092\u5c55\u958b\u3057\u3066\u3044\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended\u00a0July 31, 2020.\u00a0This is available on the company\u2019s website at\u00a0veeva.com<\/a>\u00a0under the Investors section and on the SEC\u2019s website at\u00a0sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n
\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk of a delay in compiling clinical data to support potential applications for emergency use authorizations of opaganib; the risk that the antiviral activity in the in vitro<\/em> study will not be demonstrated in clinical trials; the risk that the U.S. Phase 2 clinical study evaluating opaganib will not be successful and the risk that completion of enrollment for this clinical study will be delayed; the risk that the Company will not initiate the Phase 2\/3 study for opaganib in certain geographies, will not expand this study in additional countries and that it will not be successful; the risk that other COVID-19 patients treated with opaganib will not show any clinical improvement; the risk of a delay in applying for emergency use authorizations; the development risks of early-stage discovery efforts for a disease that is still little understood, including difficulty in assessing the efficacy of opaganib for the treatment of COVID-19, if at all; intense competition from other companies developing potential treatments and vaccines for COVID-19; the effect of a potential occurrence of patients suffering serious adverse events using opaganib under compassionate use programs, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company\u2019s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company\u2019s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company\u2019s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals, and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company\u2019s therapeutic candidates and Talicia\u00ae; (v) the Company\u2019s ability to successfully commercialize and promote Movantik\u00ae, Talicia\u00ae and Aemcolo\u00ae; (vi) the Company\u2019s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company\u2019s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company\u2019s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company\u2019s expenses, future revenues, capital requirements, and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company\u2019s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.<\/p>\n
\n[2]<\/sup><\/a> Antiviral Res., Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice<\/a>, 2018
\n[3]<\/sup><\/a> MedRxRiv, Compassionate Use of Opaganib For Patients with Severe COVID-19<\/a>, 2020
\n[i]<\/a> Movantik\u00ae<\/sup>\uff08\u30ca\u30ed\u30ad\u30bb\u30b4\u30fc\u30eb\uff09\u306e\u5b8c\u5168\u306a\u51e6\u65b9\u60c5\u5831\u306fwww.Movantik.com<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002
\n[ii]<\/a> Talicia\u00ae<\/sup>\uff08\u30aa\u30e1\u30d7\u30e9\u30be\u30fc\u30eb\u30de\u30b0\u30cd\u30b7\u30a6\u30e0\u3001\u30a2\u30e2\u30ad\u30b7\u30b7\u30ea\u30f3\u3001\u30ea\u30d5\u30a1\u30d6\u30c1\u30f3\uff09\u306e\u5b8c\u5168\u306a\u51e6\u65b9\u60c5\u5831\u306fwww.Talicia.com<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002
\n[iii]<\/a> Aemcolo\u00ae<\/sup>\uff08\u30ea\u30d5\u30a1\u30de\u30a4\u30b7\u30f3\uff09\u306e\u5b8c\u5168\u306a\u51e6\u65b9\u60c5\u5831\u306fwww.Aemcolo.com<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"